Osmotica Pharmaceuticals plc (NASDAQ:OSMT) Short Interest Update

Osmotica Pharmaceuticals plc (NASDAQ:OSMT) was the recipient of a large growth in short interest during the month of December. As of December 31st, there was short interest totalling 412,200 shares, a growth of 263.5% from the December 15th total of 113,400 shares. Approximately 1.0% of the company’s stock are sold short. Based on an average daily trading volume, of 694,000 shares, the short-interest ratio is presently 0.6 days.

Several analysts recently commented on the stock. Truist Securities reduced their target price on shares of Osmotica Pharmaceuticals from $7.00 to $5.00 and set a “buy” rating for the company in a report on Monday, October 11th. Jefferies Financial Group started coverage on shares of Osmotica Pharmaceuticals in a report on Tuesday, November 9th. They issued a “buy” rating for the company. Truist cut their price objective on shares of Osmotica Pharmaceuticals from $7.00 to $5.00 and set a “buy” rating for the company in a report on Monday, October 11th. HC Wainwright started coverage on shares of Osmotica Pharmaceuticals in a report on Thursday, December 23rd. They issued a “buy” rating and a $5.00 price objective for the company. Finally, Cantor Fitzgerald started coverage on shares of Osmotica Pharmaceuticals in a report on Friday, September 24th. They issued an “overweight” rating and a $6.00 price objective for the company. One analyst has rated the stock with a sell rating and six have given a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $5.80.

OSMT stock opened at $1.13 on Friday. Osmotica Pharmaceuticals has a 1 year low of $0.98 and a 1 year high of $4.95. The company has a 50 day simple moving average of $1.28 and a 200 day simple moving average of $2.40.

Osmotica Pharmaceuticals (NASDAQ:OSMT) last released its quarterly earnings data on Monday, November 15th. The company reported ($0.42) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.06). Osmotica Pharmaceuticals had a negative net margin of 138.76% and a negative return on equity of 81.23%. The business had revenue of $2.20 million during the quarter, compared to the consensus estimate of $2.39 million. During the same period last year, the business posted ($0.14) earnings per share. As a group, research analysts expect that Osmotica Pharmaceuticals will post -1.19 earnings per share for the current fiscal year.

In other news, COO James Schaub acquired 93,800 shares of the stock in a transaction dated Thursday, December 16th. The shares were bought at an average cost of $1.07 per share, for a total transaction of $100,366.00. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. 5.22% of the stock is currently owned by insiders.

A number of institutional investors have recently made changes to their positions in OSMT. Nations Financial Group Inc. IA ADV purchased a new position in shares of Osmotica Pharmaceuticals in the third quarter worth $37,000. Credit Suisse AG bought a new position in Osmotica Pharmaceuticals in the 2nd quarter worth about $84,000. JPMorgan Chase & Co. boosted its stake in Osmotica Pharmaceuticals by 417.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 37,606 shares of the company’s stock worth $113,000 after purchasing an additional 30,341 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in Osmotica Pharmaceuticals by 12.9% in the 2nd quarter. Goldman Sachs Group Inc. now owns 56,313 shares of the company’s stock worth $169,000 after purchasing an additional 6,455 shares in the last quarter. Finally, Ergoteles LLC bought a new position in Osmotica Pharmaceuticals in the 2nd quarter worth about $172,000. Institutional investors and hedge funds own 46.18% of the company’s stock.

Osmotica Pharmaceuticals Company Profile

Osmotica Pharmaceuticals Plc engages in the development and commercialization of products for neurology and women’s health. Its products include Upneeq, M-72, Arbaclofen ER, OS870, Divigel, OB Complete, Methylphenidate ER, Venlafaxine ER tablets (VERT), Hydromorphone ER, Sodium Benzoate/Sodium Phenylacetate, Oxybutynin ER, Prescription Prenatal Vitamins, Chlorzoxazone (Lorzone AG), Tramadol ER (ConZip AG), Nitrofurantoin and Osmodex ANDAs.

Recommended Story: Trading Ex-Dividend

Receive News & Ratings for Osmotica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Osmotica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.